Engineering Co-Stimulation-Independent T-Cells to Overcome Tumor Immunosuppression
Time: 11:30 am
day: Conference Day One R&D Track AM
Details:
- Introducing a gain-of-function gene that enhances T-Cell sensitivity to low antigen levels and bypasses CD28 costimulation
- Demonstrating resistance to PD-1 and CTLA-4 mediated suppression, improving efficacy in low-immunogenic tumors
- Exploring translational potential for TIL therapies beyond melanoma through strategic partnerships
Speakers:
